Technology | FFR Technologies | November 03, 2017

Acist Medical Systems Announces Approval and Launch of Next-Generation FFR System

Acist RXi Mini System seamlessly integrates with existing cath lab hemodynamic systems and FFR software

Acist Medical Systems Announces Approval and Launch of Next-Generation FFR System

November 3, 2017 — Acist Medical Systems Inc., a Bracco Group Company, announced the global launch of its Acist RXi Mini System, the next-generation system of its RXi Rapid Exchange FFR System. The RXi Mini System debuted at the 29th Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 2 in Denver.

The RXi Mini is designed to provide fractional flow reserve (FFR) measurements to complement angiography, provide qualitative assessment of lesion severity, and inform intervention strategy in both diagnosis and treatment of coronary and peripheral artery disease. The system is designed to seamlessly integrate with existing hemodynamic systems and FFR software. The RXi Mini offers flexible mounting configurations, a simple and intuitive user interface, and a small and unobtrusive system profile that adapts to users’ existing workflow and maximizes procedural efficiency.

The first case in the United States and the world was performed by Michael Lim, M.D., and director of cardiology at St. Louis University. During a complex case performed by Lim, the RXi Mini System was utilized to measure FFR multiple times during the procedure. Lim noted “Acist has raised the bar in making physiology accessible and easy to use in the cath lab setting.” The small RXi Mini system is about the size of a fist and connects into hospital hemodynamic systems where the measurements can be taken and recorded by lab staff, making the procedure go more smoothly and quickly. “FFR is the gold standard in diagnosing which lesions will most likely benefit from coronary interventions, including stent placement. The Acist Rapid FFR Mini RXi system makes it much simpler to perform FFR, whenever it is called for. With this advance, it continues to become easier to guide treatment decisions by invasive physiologic measurement – there really aren't that many excuses left for the interventionalist to skip this step.”

Unlike standard pressure wires, the Acist RXi Mini System and Navvus Rapid Exchange FFR MicroCatheter, allows physicians to use their 0.014-inch guide wire of choice throughout the procedure, addressing challenges of pressure wires, including accessibility in challenging anatomies, maintaining wire position, pressure‐measurement drift and ease of obtaining post‐intervention FFR.

For more information: www.acist.com

Related Content

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major